EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Clinical trials for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) explained in plain language.
Never miss a new study
Get alerted when new EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) trials appear
Sign up with your email to follow new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cholesterol-Lowering drug may boost lung cancer immunotherapy
Disease control Recruiting nowThis phase 2 trial tests whether adding tafolecimab (a cholesterol-lowering drug) to standard chemotherapy and the immunotherapy sintilimab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 40 adults who have not had prior tr…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for aggressive lung cancer: experimental drug combo enters final testing
Disease control Recruiting nowThis study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for tough lung cancer: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial tests whether the drug sacituzumab govitecan (Trodelvy) helps people with extensive stage small cell lung cancer live longer compared to standard treatments. About 695 participants who have already had one round of chemotherapy will be randomly assigned to rece…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take on tough lung cancer
Disease control Recruiting nowThis study tests a new treatment called DJI136, which uses a patient's own immune cells engineered to target a protein (DLL3) found on small cell lung cancer cells. The trial enrolls 80 adults with extensive-stage small cell lung cancer whose disease has progressed after standard…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Promising drug cocktail aims to stall aggressive lung cancer
Disease control Recruiting nowThis study tests whether combining two FDA-approved drugs—sacituzumab govitecan and an immunotherapy (atezolizumab or durvalumab)—can control tumor growth in adults with extensive-stage small cell lung cancer. Participants receive the drug combo every 21 days for up to 2 years, w…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Bindu R Potugari • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New triple therapy takes on stubborn lung cancer in early trial
Disease control Recruiting nowThis early-phase trial is testing a new oral drug called iadademstat combined with radiation therapy and the immunotherapy atezolizumab in people with extensive-stage small-cell lung cancer that has persisted, returned, or worsened after first-line treatment. The study will enrol…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE1 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New combo therapy shows promise for tough lung cancer
Disease control Recruiting nowThis study tests a new treatment for people with extensive stage small cell lung cancer, a fast-growing cancer that has spread. Participants first get a drug called tislelizumab plus chemotherapy, then chest radiation if the cancer shrinks, followed by maintenance tislelizumab fo…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Hope for aggressive lung cancer: targeted drug trial opens
Disease control Recruiting nowThis study tests a drug called teniposide in people with a fast-growing type of lung cancer (extensive-stage small cell lung cancer) that has a specific gene change (c-Myc-driven). The cancer must have gotten worse after standard treatments. The goal is to see if teniposide can s…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New immunotherapy cocktail aims to tackle tough lung cancer
Disease control Recruiting nowThis study tests whether adding extra immunotherapy drugs to standard chemotherapy can better control extensive-stage small cell lung cancer. About 180 adults who have not had prior treatment will be randomly assigned to one of three groups, all receiving the immunotherapy ivones…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Promising cocktail targets tough lung cancer
Disease control Recruiting nowThis study tests whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy and radiation can help people with extensive small cell lung cancer live longer without their cancer getting worse. About 56 adults who have not had prior treatment for this advanced can…
Matched conditions: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC